40
Participants
Start Date
January 3, 2020
Primary Completion Date
March 31, 2022
Study Completion Date
March 31, 2022
Dextenza 0.4Mg Ophthalmic Insert
The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
Topical Prednisolone
Standard of care topical drop treatment
Retina Vitreous Surgeons of Central New York, PC, Liverpool
Collaborators (1)
Ocular Therapeutix, Inc.
INDUSTRY
Patrick R. Oellers, MD
NETWORK